
The lack of dopamine through the degeneration of the nigrostriatal pathways is responsible for most of the cardinal motor symptoms of Parkinson’s disease. Ever since the seminal New England paper by dr. George Cotzias describing the clinical effect of the administration of the dopamine precursor levodopa, the main research focus has often been on motor symptoms. Non-motor symptoms and non-motor fluctuations can also be very troublesome to patients. To shed more light on these often-neglected symptoms, this review will focus on the clinical aspects of a variety of non-motor symptoms in Parkinson’s disease, discussing the evidence and lack thereof for levodopa improving (the good), having no effect (the bad), or even causing or worsening certain non-motor symptoms (the ugly). The largest body of evidence supports a role for levodopa in the treatment of non-motor fluctuations. More dedicated clinical trials as well as novel therapies targeting non-dopaminergic mechanisms are needed to better address many non-motor symptoms.
Device‑aided therapies (DATs) are important treatment options for people with Parkinson’s disease whose symptoms can no longer be adequately controlled with oral or transdermal medication. They offer the potential to maintain or restore quality of life when conventional approaches are insufficient. Identifying which individuals with PD should be referred for DAT assessment, and then selecting the most appropriate therapy for each individual, requires careful evaluation of multiple factors. These extend beyond efficacy and tolerability to include practical, real‑world considerations shaped by a person’s personal circumstances, preferences, and care systems. To support clinicians in the initial step of recognizing when a person may be ready to transition to a DAT, several screening tools have been developed. Among these, D‑DATS is a practical, precise, and easy‑to‑use three‑factor tool designed for routine clinical practice. Validation studies indicate that D‑DATS outperforms commonly used criteria such as the ‘5‑2‑1’ rule and MANAGE‑PD, with respect to its specificity, reducing unnecessary or premature referrals. This article reviews the importance of accurate selection of suitable people with PD using a precise tool such as D‑DATS, and explores the real‑world considerations that can help guide the choice between DAT options. As motor efficacy, expressed as the reduction in the number of daily OFF-time hours, is broadly comparable across all DATs, the final decision often hinges on additional factors, like safety, long-term maintenance, and practical and patient‑centered factors. To support this process, we propose a decision‑tree flow chart to help clinicians navigate therapy selection in partnership with their patients. Ultimately, shared decision‑making, supported by ongoing reassessment and monitoring, is essential to ensure the long‑term success of whichever DAT is chosen.
Parkinson’s disease (PD) screening can identify people needing clinical assessment but does not itself provide continuing care. Drawing on Thailand’s smartphone-based CheckPD implementation and selected literature, this conceptual review proposes CheckBRAIN, a platform linking screening to personalised brain-health care. All CheckPD participants would be offered voluntary entry, while clinician-led assessment would proceed without delay when clinically indicated. Concerning screening results, new or progressive symptoms, clinically defined high-risk syndromes, diagnostic uncertainty or medication-related problems would trigger clinical review, while people with established PD could enter directly. A personal brain-health portfolio links multidomain functioning, systemic and environmental context, priorities, actions, responsible persons or services and review dates. The six-domain SHAPES framework supports priority setting without creating another diagnostic score. Actions may include diagnostic assessment, medication review or pharmacotherapy, rehabilitation, cue-linked daily habits, social support, and service-level responses to practical barriers such as transport, digital access, referral navigation or unavailable services. Primary-care teams would coordinate longitudinal review, community workers would support assisted or non-digital participation, and specialists would contribute according to clinical need. Intended benefits include understandable next steps, fewer unresolved referrals, support for everyday function and participation, and clearly defined roles for care partners with the participant’s consent. We outline staged co-design and evaluation of feasibility, safety, functioning, participation, caregiver burden, equity, service use and costs. CheckBRAIN is not intended as a population registry and has no fixed national enrolment target. It remains a proposed care architecture, not a validated intervention or evidence of PD prevention or cost saving. Its intended contribution is accountable continuity between identified needs, appropriate care and reviewed outcomes.